Physician profile
Devaughn Bell
NPI 1629525597
$2,351.00
in general payments reported to CMS, 2019-2025
21 companies · $966 in 2025
The $966 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $569 · 2023: $653 · 2024: $163 · 2025: $966.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,782.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,781.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $463.91 | 2022-2025 | |
| Gilead Sciences, INC. | $455.62 | 2023-2025 | Epclusa |
| Novo Nordisk INC | $423.38 | 2022-2025 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $228.59 | 2022-2023 | Breztri, Farxiga |
| Viiv Healthcare Company | $140.47 | 2023-2025 | Apretude, Cabenuva |
| Lilly USA, LLC | $138.50 | 2022-2025 | Mounjaro |
| Pfizer INC. | $97.34 | 2023-2025 | |
| Hologic Sales and Service, LLC | $49.01 | 2025 | Aptima, Thinprep 2000 Processor |
| Indivior INC. | $48.86 | 2025 | Sublocade |
| Glaxosmithkline, LLC. | $46.31 | 2022-2023 | Shingrix |
| Braeburn INC. | $45.31 | 2024 | Brixadi |
| Bayer Healthcare Pharmaceuticals INC. | $29.39 | 2022 | |
| Dynavax Technologies Corporation | $25.52 | 2022 | |
| Sobi, INC | $23.96 | 2023 | |
| Abbott Laboratories | $23.20 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $20.54 | 2022 | |
| Alkermes, INC. | $20.20 | 2025 | Vivitrol |
| Cranial Technologies, INC | $18.63 | 2024 | Doc Band |
| Verrica Pharmaceuticals INC. | $18.21 | 2024 | Ycanth |
| Lundbeck LLC | $17.47 | 2025 | Abilify Asimtufii |
| Xeris Pharmaceuticals, INC. | $16.58 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devaughn Bell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.